TABLE 3.
Number of antibiograms reporting pathogen-drug test combinations that are not recommended by CLSI for routine or supplemental reporting
Numbers indicate the number of facility antibiograms (of 32 participating facilities) reporting this pathogen-drug test combination as percent susceptible on their cumulative antibiogram. Overall, 20 (64%) of 32 antibiograms contained at least one pathogen-drug combination not recommended for routine or supplemental reporting. Gray shading indicates combinations considered to be serious errors. Thirteen (41%) of 32 antibiograms contained at least one serious error. Abbreviations: Amp-sulbactam, ampicillin-sulbactam; Pip-Tazo, piperacillin-tazobactam; TMP/SMX, trimethoprim-sulfamethoxazole; Quin-dalfo, quinupristin-dalfopristin.